Ultrasound-triggered herceptin liposomes for breast cancer therapy

Abstract The functionalization of liposomes with monoclonal antibodies is a potential strategy to increase the specificity of liposomes and reduce the side-effects associated with chemotherapeutic agents. The active targeting of the Human Epidermal growth factor Receptor 2 (HER2), which is overexpre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amal Elamir, Saniha Ajith, Nour Al Sawaftah, Waad Abuwatfa, Debasmita Mukhopadhyay, Vinod Paul, Mohammad H. Al-Sayah, Nahid Awad, Ghaleb A. Husseini
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/17aa7a8189b04aab8622634e904599a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:17aa7a8189b04aab8622634e904599a6
record_format	dspace
spelling	oai:doaj.org-article:17aa7a8189b04aab8622634e904599a62021-12-02T14:17:19ZUltrasound-triggered herceptin liposomes for breast cancer therapy10.1038/s41598-021-86860-52045-2322https://doaj.org/article/17aa7a8189b04aab8622634e904599a62021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86860-5https://doaj.org/toc/2045-2322Abstract The functionalization of liposomes with monoclonal antibodies is a potential strategy to increase the specificity of liposomes and reduce the side-effects associated with chemotherapeutic agents. The active targeting of the Human Epidermal growth factor Receptor 2 (HER2), which is overexpressed in HER2 positive breast cancer cells, can be achieved by coating liposomes with an anti-HER2 monoclonal antibody. In this study, we synthesized calcein and Doxorubicin-loaded immunoliposomes functionalized with the monoclonal antibody Trastuzumab (TRA). Both liposomes were characterized for their size, phospholipid content and antibody conjugation. Exposing the liposomes to low-frequency ultrasound (LFUS) triggered drug release which increased with the increase in power density. Trastuzumab conjugation resulted in enhancing the sensitivity of the liposomes to LFUS. Compared to the control liposomes, TRA-liposomes showed higher cellular toxicity and higher drug uptake by the HER2 + cell line (SKBR3) which was further improved following sonication with LFUS. Combining immunoliposomes with LFUS is a promising technique in the field of targeted drug delivery that can enhance efficiency and reduce the cytotoxicity of antineoplastic drugs.Amal ElamirSaniha AjithNour Al SawaftahWaad AbuwatfaDebasmita MukhopadhyayVinod PaulMohammad H. Al-SayahNahid AwadGhaleb A. HusseiniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Amal Elamir Saniha Ajith Nour Al Sawaftah Waad Abuwatfa Debasmita Mukhopadhyay Vinod Paul Mohammad H. Al-Sayah Nahid Awad Ghaleb A. Husseini Ultrasound-triggered herceptin liposomes for breast cancer therapy
description	Abstract The functionalization of liposomes with monoclonal antibodies is a potential strategy to increase the specificity of liposomes and reduce the side-effects associated with chemotherapeutic agents. The active targeting of the Human Epidermal growth factor Receptor 2 (HER2), which is overexpressed in HER2 positive breast cancer cells, can be achieved by coating liposomes with an anti-HER2 monoclonal antibody. In this study, we synthesized calcein and Doxorubicin-loaded immunoliposomes functionalized with the monoclonal antibody Trastuzumab (TRA). Both liposomes were characterized for their size, phospholipid content and antibody conjugation. Exposing the liposomes to low-frequency ultrasound (LFUS) triggered drug release which increased with the increase in power density. Trastuzumab conjugation resulted in enhancing the sensitivity of the liposomes to LFUS. Compared to the control liposomes, TRA-liposomes showed higher cellular toxicity and higher drug uptake by the HER2 + cell line (SKBR3) which was further improved following sonication with LFUS. Combining immunoliposomes with LFUS is a promising technique in the field of targeted drug delivery that can enhance efficiency and reduce the cytotoxicity of antineoplastic drugs.
format	article
author	Amal Elamir Saniha Ajith Nour Al Sawaftah Waad Abuwatfa Debasmita Mukhopadhyay Vinod Paul Mohammad H. Al-Sayah Nahid Awad Ghaleb A. Husseini
author_facet	Amal Elamir Saniha Ajith Nour Al Sawaftah Waad Abuwatfa Debasmita Mukhopadhyay Vinod Paul Mohammad H. Al-Sayah Nahid Awad Ghaleb A. Husseini
author_sort	Amal Elamir
title	Ultrasound-triggered herceptin liposomes for breast cancer therapy
title_short	Ultrasound-triggered herceptin liposomes for breast cancer therapy
title_full	Ultrasound-triggered herceptin liposomes for breast cancer therapy
title_fullStr	Ultrasound-triggered herceptin liposomes for breast cancer therapy
title_full_unstemmed	Ultrasound-triggered herceptin liposomes for breast cancer therapy
title_sort	ultrasound-triggered herceptin liposomes for breast cancer therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/17aa7a8189b04aab8622634e904599a6
work_keys_str_mv	AT amalelamir ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT sanihaajith ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT nouralsawaftah ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT waadabuwatfa ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT debasmitamukhopadhyay ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT vinodpaul ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT mohammadhalsayah ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT nahidawad ultrasoundtriggeredherceptinliposomesforbreastcancertherapy AT ghalebahusseini ultrasoundtriggeredherceptinliposomesforbreastcancertherapy
_version_	1718391591655178240

Ultrasound-triggered herceptin liposomes for breast cancer therapy

Ejemplares similares